Department of Basic Medical Sciences, Luohe Medical College, Luohe 462000, China; Henan Province Engineering & Technology Research Center of Foods for Special Medical Purpose, Luohe Medical College, Luohe 462000, China.
Department of Basic Medical Sciences, Luohe Medical College, Luohe 462000, China.
Int Immunopharmacol. 2024 Dec 25;143(Pt 1):113329. doi: 10.1016/j.intimp.2024.113329. Epub 2024 Oct 14.
Neoantigen, unique peptides resulting from tumor-specific mutations, represent a promising frontier in oncology for personalized cancer immunotherapy. Their unique features allow for the development of highly specific and effective cancer treatments, which can potentially overcome the limitations of conventional therapies. This paper explores the current prospects and challenges associated with the application of neoantigens in oncology. We examine the latest advances in neoantigen identification, vaccine development, and adoptive T cell therapy. Additionally, we discuss the obstacles related to neoantigen heterogeneity, immunogenicity prediction, and the tumor microenvironment. Through a comprehensive analysis of current research and clinical trials, this paper aims to provide a detailed overview of how neoantigens could revolutionize cancer treatment and the hurdles that must be overcome to realize their full potential.
肿瘤特异性突变产生的新抗原是肿瘤学中个性化癌症免疫治疗的一个很有前途的领域。它们独特的特征允许开发高度特异性和有效的癌症治疗方法，这有可能克服传统疗法的局限性。本文探讨了新抗原在肿瘤学中的应用相关的现状和挑战。我们研究了新抗原鉴定、疫苗开发和过继性 T 细胞治疗方面的最新进展。此外，我们还讨论了与新抗原异质性、免疫原性预测和肿瘤微环境相关的障碍。通过对当前研究和临床试验的全面分析，本文旨在详细介绍新抗原如何彻底改变癌症治疗，以及为了充分发挥其潜力而必须克服的障碍。
